The ESG vision of Sino Biopharm is to effectively practice our mission of "improving the quality and protecting the dignity of human life" through high-quality ESG management, respond to the United Nations Sustainable Development Goals, support the Healthy China initiative, seek health and well-being for more patients, and make more diseases to be treated. Meanwhile, we control risks, seize opportunities, promote the harmonious development of the company, employees, society and environment, provide strong support for the sustainable development of company, and create long-term value for ourselves and partners from all sectors.The ESG vision of Sino Biopharm is to effectively practice our mission of "improving the quality and protecting the dignity of human life" through high-quality ESG management, respond to the United Nations Sustainable Development Goals, support the Healthy China initiative, seek health and well-being for more patients, and make more diseases to be treated. Meanwhile, we control risks, seize opportunities, promote the harmonious development of the company, employees, society and environment, provide strong support for the sustainable development of company, and create long-term value for ourselves and partners from all sectors.

To ensure the realization of the Sino Biopharm ESG vision, the Group has formulated the ESG governance strategy based on "CARE", with "Cure, Accessible, Relationship, Environmental" as the four-core direction, to integrate the ESG vision with the development strategy of the Group, and promote the high-quality and sustainable development of the Group's business.To ensure the realization of the Sino Biopharm ESG vision, the Group has formulated the ESG governance strategy based on "CARE", with "Cure, Accessible, Relationship, Environmental" as the four-core direction, to integrate the ESG vision with the development strategy of the Group, and promote the high-quality and sustainable development of the Group's business.

Sino Biopharm continuously improves its ESG governance structure. With the Board as the responsible, decision-making and supervisory body for ESG, we have established the board-level Environment, Social and Governance (ESG) committee, to oversee major ESG-related issues of the Group and to advise the Board on ESG risks, opportunities, policies and actions. At the ESG management level, the Group has established an ESG Working Management Committee with the Group's senior management acting as the standing committee members, and the persons in charge of the Group's ESG-related functions and certain major member companies as the committee members. They are responsible for continuously improving the internal supervision of ESG risks, organizing the implementation of the Board's ESG strategies and requirements, reviewing ESG risks and opportunities in a timely manner based on factors such as the macro environment and business changes, and regularly reviewing the annual ESG work report and ESG-related information disclosure. In order to facilitate the implementation of ESG management work, the Group has also established the Office for ESG Department and ESG Work Management Committee, a dedicated ESG management department responsible for the overall planning, coordinating, organizing and promoting the execution of ESG tasks. The Group has formulated the "Charter of the Sino Biopharmaceutical ESG Working Management Committee" and the "Sino Biopharmaceutical Sustainable Management System" to regulate the relevant responsibilities and working mechanisms of the above ESG governance structure.